# Erasca data add to pressure facing Revolution’s breakthrough cancer drug

Source: [BioPharma Dive - Latest News](https://www.biopharmadive.com/news/erasca-kras-pancreatic-cancer-drug-results-revolution-rasonque/875314/) · 2026-11-20 · Medicine
Page: https://themorning.science/story/erasca-data-add-to-pressure-facing-revolution-s-breakthrough-cancer-drug-4a2076737cfebca2
Kind: research · Impact: medium

## In brief

- Erasca reported data on its KRAS-targeted drug in pancreatic cancer, adding pressure on Revolution Medicines' drug Rasonque, according to BioPharma Dive.
- BioPharma Dive says Rasonque is already off to one of the best oncology launches in history, but certain limitations leave room for rivals such as Erasca, which is nearing the start of a Phase 3 trial.
- New Phase I/II results reported by Medical Xpress show daraxonrasib combined with chemotherapy caused substantial tumor shrinkage in patients with metastatic pancreatic cancer.

## Why it matters

Competition is forming around KRAS-targeted treatment for pancreatic cancer, and the limitations of the leading drug may shape which approaches reach later-stage trials.

## Timeline

- 2026-11-20: Erasca data reported, adding pressure on Revolution Medicines' Rasonque
- 2026-11-20: Phase I/II results show daraxonrasib plus chemotherapy shrank tumors in metastatic pancreatic cancer

## Coverage

- [Metastatic pancreatic cancer responds well to treatment with combination of daraxonrasib and chemotherapy](https://medicalxpress.com/news/2026-11-metastatic-pancreatic-cancer-treatment-combination.html) — Medical Xpress - latest medical and health news stories, 2026-11-20
- [Erasca data add to pressure facing Revolution’s breakthrough cancer drug](https://www.biopharmadive.com/news/erasca-kras-pancreatic-cancer-drug-results-revolution-rasonque/875314/) — BioPharma Dive - Latest News, 2026-11-20

Tags: pancreatic cancer, kras, daraxonrasib, oncology drugs, clinical trials

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
